Abstract:DNA methylation can deactivate tumor suppressor genes thus causing cancers. Two DNA methylation inhibitors have been approved by the Food and Drug Administration (FDA) and have entered clinical use. However, these inhibitors are nucleoside analogues that can be incorporated into DNA or RNA and induce significant side effects. DNMT1 and DNMT3 are key enzymes involved in DNA methylation. In the acute myeloid leukemia model, a non-nucleoside DNMT1-specific inhibitor has shown lower toxicity and improved pharmacokinetics compared to traditional nucleoside drugs. DNMT3 is also implicated in certain specific cancers. Thus, developing non-nucleoside inhibitors for DNMT1 or DNMT3 can help in understanding their roles in carcinogenesis and provide targeted treatment options in certain cancers. Although no non-nucleoside inhibitors have yet entered clinical trials, in this review, we focus on DNMT1 or DNMT3 selective inhibitors. For DNMT1 selective inhibitors, we have compiled information on the repurposed drugs, derivative compounds and selective inhibitors identified through virtual screening. Additionally, we have outlined potential targets for DNMT1, including protein-protein complex, RNA mimics and aptamers. Compared to DNMT1, research on DNMT3-specific inhibitors has been less extensive. In this context, our exploration has identified a limited number of molecular inhibitors, and we have proposed specific long non-coding RNAs (lncRNAs) as potential contributors to the selective inhibition of DNMT3. This collective effort aims to offer valuable insights into the development of non-nucleoside inhibitors that selectively target DNMT1 or DNMT3.

DNA methyltransferase inhibitors: an updated patent review (2012-2015)

Progress in combined treatments of myelodysplastic syndrome and acute myeloid leukemia based on DNA methyltransferase inhibitors

DNA Methyltransferases: Emerging Targets for the Discovery of Inhibitors As Potent Anticancer Drugs

DNA Methyltransferase Inhibitors and Their Therapeutic Potential

DNA Methyltransferase Inhibitors and Their Therapeutic Potential.

Epigenetic Therapy: Research Progress of Decitabine in the Treatment of Solid Tumors

Targeting DNA methyltransferases for cancer therapy

Recent progress in DNA methyltransferase inhibitors as anticancer agents

Non-nucleoside inhibitors of DNMT1 and DNMT3 for targeted cancer therapy

DNA Methyltransferase Inhibitors: Catalysts for Antitumour Immune Responses

DNA methyltransferase inhibitors in cancer: From pharmacology to translational studies

Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs

DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application

Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010–present)

Discovery of novel non-nucleoside inhibitors with high potency and selectivity for DNA methyltransferase 3A

Small molecules targeting selected histone methyltransferases (HMTs) for cancer treatment: Current progress and novel strategies

An updated patent review of protein arginine N-methyltransferase inhibitors (2019-2022)

Selective non-nucleoside inhibitors of human DNA methyltransferases active in cancer including in cancer stem cells.

Decitabine, a New Star in Epigenetic Therapy: the Clinical Application and Biological Mechanism in Solid Tumors.

An update patent review of MDM2-p53 interaction inhibitors (2019-2023)

Fragment-based discovery of new potential DNMT1 inhibitors integrating multiple pharmacophore modeling, 3D-QSAR, virtual screening, molecular docking, ADME, and molecular dynamics simulation approaches